SRP-9001

delandistrogene moxeparvovec · Sarepta Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SRP-9001, covering 2026-04-06 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 1]

See pricing